All In MedTech

Device Trial Radar · NCT03396172

FreeDom: Innovative Strategy for the Management of COPD Exacerbations

FreeDom : Innovative Strategy for the Management of COPD Exacerbations Combining Early Hospitalisation Discharge, Automated Oxygen Weaning at Home, Telemedicine and Tele-rehabilitation

Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingRandomized with 100 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

100

Planned (sponsor's estimate)

Start

May 24, 2018

Primary completion

Jun 2030

Study completion Dec 2030

Sponsor

Lead sponsor
Laval UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jan 10, 2018

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main objective of the study is to assess the "FreeDom" innovative strategy (FreeO2 at Domicile) to reduce hospitalization duration in patients with COPD exacerbation. This strategy associates early hospital discharge, automated O2 flow weaning with FreeO2 system, telemedicine and tele-rehabilitation. The main hypothesis of this study is that the FreeDom strategy will reduce the number of hospitalization day by 50 percent at day 30.

Conditions

  • Oxygen Deficiency
  • COPD Exacerbation

Interventions

  • ControlOther

    The hospitalization will take place in the usual setting and the hospital discharge will be decided by pulmonologists according to the usual criteria

  • FreeDomDevice

    Early return home, patients using an innovative device that automatically adjusts and wean the oxygen flow (FreeO2 system) coupled to telemedicine and tele-rehabilitation

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The number of hospital days during COPD exacerbation at day 30.Time frame: 30 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Institut Universitaire de Cardiologie et de Pneumologie de Québec

    Québec, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.